Cencora Corp has been performing impressively over the past three years, gaining increased attention from investors after a spectacular price run. The company has consistently beaten earnings estimates. This trend continued into Q1 of 2026, with earnings per share surpassing whilst revenues slightly fell short of expectations. Despite this mixed performance,
Cencora shares have been trending upwards due to a swift strategic shift stemming from Specialty Expansion and OneOncology. The company foresees significant cash flow by FY26, however, there's noteworthy international challenges affecting growth. Their alliance with Curant is deepening its services in rare disease, enhancing the company's growth story.
Cencora's OneOncology acquisition and lifted guidance furthers the growth narrative. It expects a 2026 adjusted EPS range of $17.45 to $17.75. Despite these developments,
Cencora’s Q4 CY2025 revenues were a miss, leading to a drop in price target by Evercore ISI. This, however, resulted in an undervaluation of the company's assets, creating potential investment opportunities, especially with its strategic investments fuelling growth amid marginal disruptions. Nonetheless,
Cencora's outlook remains bullish as it continues to deliver robust results, expand globally, and pursue innovative strategic initiatives.
Cencora COR News Analytics from Fri, 01 Aug 2025 07:00:00 GMT to Sat, 07 Feb 2026 18:32:00 GMT -
Rating 6
- Innovation 3
- Information 9
- Rumor -2
